We now know that gene expression in cancer cells is altered not only via genetic changes but also through modifications of the chromatin landscape including DNA methylation, histone modifications and chromatin remodelling. Working in the Division of Cancer Epigenetics Unit, my current research focuses on those epigenetic changes with a particular interest in pancreatic cancer (supported by Pancreatic Cancer Research Fund (www.pcrf.org.uk) and the Academy of Medical Sciences). Through detailed characterisation of its epigenomic landscape and the association with drug response, the main aim is to identify new epigenetic treatment strategies for pancreatic cancer with identification of biomarkers to select those patients who will benefit. Ultimately, this information will be used to test new approaches for treatment of pancreatic cancer in the clinic.
I qualified in Medicine at the University of Utrecht, The Netherlands, in 2006 and completed my PhD research in 2010 at Barts Cancer Institute under supervision of Prof Hemant Kocher and Prof Ian Hart, studying the role of stromal cells in modulating pancreatic cancer growth and progression. Having been awarded a Clinical Lectureship by the National Institute of Health Research (UK), I joined Imperial College London in 2013 as a Clinical Lecturer to finish my specialty training in Medical Oncology and continue my research with a particular interest in pancreatic cancer.
For more information about the Epigenetics Unit, please see
Froeling FEM, Stebbing J, 2014, Uncaria tomentosa, the cat's whiskers or claws?, Lancet Oncology, Vol:15, ISSN:1470-2045, Pages:1299-1300
Froeling FEM, Seckl MJ, 2014, Gestational trophoblastic tumours: an update for 2014., Curr Oncol Rep, Vol:16
et al., 2013, Ezrin expression is an independent prognostic factor in gastro-intestinal cancers., J Gastrointest Surg, Vol:17, Pages:2082-2091
et al., 2013, Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes., J Pathol, Vol:230, Pages:107-117
et al., 2013, RhoC interacts with integrin α5β1 and enhances its trafficking in migrating pancreatic carcinoma cells., Plos One, Vol:8